USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer

Biochemical and Biophysical Research Communications

Volumn 460, Issue 3, 2015, Pages 703-708

  Xiao, Haibo ^a   Tian, Yue ^b   Yang, Yang ^a   Hu, Fengqing ^a   Xie, Xiao ^a   Mei, Ju ^a   Ding, Fangbao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cyclooxygenase 2; Deubiquitination; Non small cell lung cancer; Prostaglandin E2; Ubiquitin specific protease 22

Indexed keywords

CYCLOOXYGENASE 2; THIOL ESTER HYDROLASE; USP22 PROTEIN, HUMAN;

CELL PROLIFERATION; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; ONCOGENE; PATHOLOGY; PHYSIOLOGY; PROTEIN STABILITY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; HUMANS; LUNG NEOPLASMS; ONCOGENES; PROTEIN STABILITY; SUBSTRATE SPECIFICITY; THIOLESTER HYDROLASES;

EID: 84937764465     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.03.093     Document Type: Article

References (29)

1. M. Reck, S. Popat, N. Reinmuth, D. De Ruysscher, K.M. Kerr, S. Peters, and E.G.W. Grp Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol. 25 2014 27 39
2. S. Sun, J.H. Schiller, M. Spinola, and J.D. Minna New molecularly targeted therapies for lung cancer J. Clin. Invest. 117 2007 2740 2750
3. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, and M.J. Thun Cancer statistics, 2006 CA Cancer J. Clin. 56 2006 106 130
4. J. Ning, J. Zhang, W. Liu, Y. Lang, Y. Xue, and S. Xu Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer Eur. J. Histochem. 56 2012 e46
5. X.Y. Zhang, M. Varthi, S.M. Sykes, C. Phillips, C. Warzecha, W. Zhu, A. Wyce, A.W. Thorne, S.L. Berger, and S.B. McMahon The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression Mol. Cell 29 2008 102 111
6. H.J. Lee, M.S. Kim, J.M. Shin, T.J. Park, H.M. Chung, and K.H. Baek The expression patterns of deubiquitinating enzymes, USP22 and Usp22 Gene Expr. Patterns 6 2006 277 284
7. H. Wang, Y.P. Li, J.H. Chen, S.F. Yuan, L. Wang, J.L. Zhang, Q. Yao, N.L. Li, J.F. Bian, J. Fan, J. Yi, and R. Ling Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma Tumor Biol. 34 2013 1635 1639
8. M. Yang, Y.D. Liu, Y.Y. Wang, T.B. Liu, T.T. Ge, and G. Lou Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics Tumor Biol. 35 2014 929 934
9. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenases 1 and 2 Annu Rev. Pharmacol. Toxicol. 38 1998 97 120
10. K. Riedl, K. Krysan, M. Pold, H. Dalwadi, N. Heuze-Vourc'h, M. Dohadwala, M. Liu, X. Cui, R. Figlin, J.T. Mao, R. Strieter, S. Sharma, and S.M. Dubinett Multifaceted roles of cyclooxygenase-2 in lung cancer Drug Resist. Update 7 2004 169 184
11. A. Greenhough, H.J. Smartt, A.E. Moore, H.R. Roberts, A.C. Williams, C. Paraskeva, and A. Kaidi The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis 30 2009 377 386
12. J. Brabender, J. Park, R. Metzger, P.M. Schneider, R.V. Lord, A.H. Holscher, K.D. Danenberg, and P.V. Danenberg Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer Ann. Surg. 235 2002 440 443
13. F.R. Khuri, H. Wu, J.J. Lee, B.L. Kemp, R. Lotan, S.M. Lippman, L. Feng, W.K. Hong, and X.C. Xu Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer Clin. Cancer Res. 7 2001 861 867
14. P. Rockwell, H. Yuan, R. Magnusson, and M.E. Figueiredo-Pereira Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2) Arch. Biochem. Biophys. 374 2000 325 333
15. J. Shao, H. Sheng, H. Inoue, J.D. Morrow, and R.N. DuBois Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells J. Biol. Chem. 275 2000 33951 33956
16. P.M. Voorhees, E.C. Dees, B. O'Neil, and R.Z. Orlowski The proteasome as a target for cancer therapy Clin. Cancer Res. 9 2003 6316 6325
17. D. Levens How the c-myc promoter works and why it sometimes does not J. Natl. Cancer Inst. Monogr. 2008 41 43
18. U. Rabenhorst, R. Beinoraviciute-Kellner, M.L. Brezniceanu, S. Joos, F. Devens, P. Lichter, R.J. Rieker, J. Trojan, H.J. Chung, D.L. Levens, and M. Zornig Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth Hepatology 50 2009 1121 1129
19. B.S. Atanassov, and S.Y. Dent USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1 EMBO Rep. 12 2011 924 930
20. J. Liu, S. Shaik, X. Dai, Q. Wu, X. Zhou, Z. Wang, and W. Wei Targeting the ubiquitin pathway for cancer treatment Biochim. Biophys. Acta 1855 2014 50 60
21. F. Colland The therapeutic potential of deubiquitinating enzyme inhibitors Biochem. Soc. Trans. 38 2010 137 143
22. Y. Fang, D. Fu, and X.Z. Shen The potential role of ubiquitin c-terminal hydrolases in oncogenesis Biochim. Biophys. Acta 1806 2010 1 6
23. H. Zhang, Z. Li, and K. Wang Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo Oncol. Rep. 31 2014 1954 1960
24. H. Murata, S. Tsuji, M. Tsujii, Y. Sakaguchi, H.Y. Fu, S. Kawano, and M. Hori Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells Lab. Invest. 84 2004 1050 1059
25. U.R. Mbonye, M. Wada, C.J. Rieke, H.Y. Tang, D.L. DeWitt, and W.L. Smith The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system J. Biol. Chem. 281 2006 35770 35778
26. H. Neuss, X.H. Huang, B.K.J. Hetfeld, R. Deva, P. Henklein, S. Nigam, J.W. Mall, W. Schwenk, and W. Dubiel The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs J. Mol. Med. JMM 85 2007 961 970
27. Y. Zhao, G. Lang, S. Ito, J. Bonnet, E. Metzger, S. Sawatsubashi, E. Suzuki, X. Le Guezennec, H.G. Stunnenberg, A. Krasnov, S.G. Georgieva, R. Schule, K. Takeyama, S. Kato, L. Tora, and D. Devys A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing Mol. Cell 29 2008 92 101
28. E. Chipumuro, and M.A. Henriksen The ubiquitin hydrolase USP22 contributes to 3′-end processing of JAK-STAT-inducible genes FASEB J. 26 2012 842 854
29. F. Ding, C. Bao, Y. Tian, H. Xiao, M. Wang, X. Xie, F. Hu, and J. Mei USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inhibition Int. J. Mol. Sci. 16 2014 307 320